Vistagen gets FDA feedback on fasedienol Phase 3 path, reports Q2 FY2027 results
FDA offered feedback on a planned Phase 3 study of fasedienol in social anxiety disorder as Vistagen posted a $10.7 million net loss and $20 million in cash as of September 30, 2026.
SEC filing